alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–22 of 22 studies by Biessels GJ · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial

✓ Peer-reviewed alzhub usefulness score 83 out of 100. Diabetes care 2019-08-09

In a large international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease, linagliptin did not modulate cognitive decline over 2.5 years. 2 key findings →

Participants: 1,545 Evidence: high

Full summary, score breakdown and related studies → Original source

SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Neurology 2024-09-18

In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. 5 key findings →

Design: cohort Participants: 358,862 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Midlife risk score for the prediction of dementia four decades later

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-09-10

A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →

Design: cohort study Participants: 2,767 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral microinfarcts: a systematic review of neuropathological studies

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2012-01-11

Vascular cognitive impairment is an umbrella term for cognitive dysfunction associated with and presumed to be caused by vascular brain damage. 2 key findings →

Participants: 10,515 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review

✓ Peer-reviewed alzhub usefulness score 65 out of 100. European journal of pharmacology 2008-03-04

Vascular risk factors, such as type 2 diabetes, hypertension, obesity and dyslipidaemia often co-occur. 3 key findings →

Design: longitudinal study Participants: 14 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-04-09

White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Stroke 2016-12-15

Two decades of epidemiological research shows that silent cerebrovascular disease is common and is associated with future risk for stroke and dementia. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cognitive function in patients with diabetes mellitus: guidance for daily care

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Lancet. Neurology 2015-02-16

Diabetes mellitus is associated with an increase in the risk of dementia and the proportion of patients who convert from mild cognitive impairment (MCI) to dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cortical microinfarcts on 3T MRI: Clinical correlates in memory-clinic patients

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-05-05

This is the first study to assess cerebral microinfarcts (CMIs) on 3 tesla (3T) magnetic resonance imaging (MRI) in a memory clinic population. 4 key findings →

Participants: 238 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive dysfunction in diabetes: how to implement emerging guidelines

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Diabetologia 2019-08-16

Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognised as an important comorbidity and complication of diabetes that affects an individual's well-being and diabetes management, and is associated with diabetes treatment-related complications. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2016-02-03

This study provides evidence for heterogeneous pathologic substrates and possibly different pathophysiologic mechanisms underlying MRI-observed cortical microbleeds in the context of advanced CAA and Alzheimer disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

In vivo detection of cerebral cortical microinfarcts with high-resolution 7T MRI

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2012-12-19

Cerebrovascular disease has an important role in cognitive decline and dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ageing and diabetes: implications for brain function

✓ Peer-reviewed alzhub usefulness score 45 out of 100. European journal of pharmacology 2002-04-01

Diabetes mellitus is associated with moderate cognitive deficits and neurophysiological and structural changes in the brain, a condition that may be referred to as diabetic encephalopathy. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Visit-to-Visit Blood Pressure Variability, Glycemic Status and the Risk of Dementia, Stroke, and All-Cause Mortality: A UK Biobank Cohort Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-13

Absolute BPV was associated with mortality, and DBP and MAP variability with overall stroke, after accounting for glycemic status and mean blood pressure. 5 key findings →

Design: prospective cohort Participants: 57,611 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed